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Atherothrombotic disease (ATD) is a progressivedisorder and its most common clinicalmanifestations, acute myocardial infarction and
stroke, are responsible for the highest morbidity and
mortality rates in the Western world. Sudden death due to
infarction with no prior symptoms occurs in 50% of men and
64% of women.1 
One of the main tools to control the incidence of vascular dis-
ease is prevention. Formulas are available to estimate cardio-
vascular risk (Framingham risk score, etc.)2 They are based
on epidemiological studies that determine the risk of suffer-
ing a cardiovascular event (fatal or non-fatal) within 5 to 10
years.3 While the available system to calculate cardiovascular
risk is easily generalisable, and universal, it does present
some difficulties. The main drawback is its low sensitivity for
detecting individuals at a high risk to suffer a cardiovascular
event. Large epidemiological studies show that 62% of sub-
jects with a prior history of myocardial infarction present
none or only one of the cardiovascular risk factors,4 which,
undoubtedly, prevents them from being properly identified at
a time to take effective preventive actions. 
In recent years, there have been significant technological
advances in medical imaging techniques, particularly in
the field of vascular disease. Below, we describe the ad-
vantages, disadvantages and uses of imaging techniques in
the general population and in chronic kidney disease
(CKD) patients. 
GENERAL POPULATION 
Various methods have been used for the diagnosis and
prevention of cardiovascular disease (CVD). Studies on the
calcification of coronary arteries using helicoidal or
multidetector computed tomography (CT) accurately
measure coronary calcium content (coronary calcium
score). However, this method is not useful in patients at a
low cardiovascular risk according to traditional estimation
methods.5 Although coronary CT has a high specificity to
diagnose coronary atherosclerosis, and some studies
suggest that it directly correlates to mortality over time,6
this is a costly technique that requires advanced
technology, and therefore, it cannot be used for the early
detection of ATD in the general population. More
significantly, coronary calcium scores measure the
presence of calcium deposition in the coronary arteries, and
therefore, it fails to diagnose early stages of vascular
disease, as ATD is a progressive vascular disorder, and
calcification only occurs in its advanced stages. 
Coronary arteriography has recently been complemented
with the use of intravascular ultrasound7 techniques that
offer a more precise diagnosis of coronary atherosclerosis.
However, this method is painful and expensive, and
therefore cannot be considered a good option for the early
detection of ATD in the general population. 
Carotid ultrasound has several advantages compared to the
previously described methods, but the use of this technique
for early diagnosis of atherosclerosis is not generalised.
Ultrasound of supra-aortic trunks is used in patients with
symptomatic atherosclerosis, particularly those who have
suffered a stroke. As these patients have already suffered an
event due to arterial disease, we can only provide a diagnosis
or confirmation of a suspected diagnosis and establish the
surgical indication, rather than implementing preventive
therapeutic interventions. 
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Applying this technique in early diagnosis of ATD requires
rigorous training of the technician and the specialist reading
of the properly acquired images in order to obtain accurate
parameters for the early diagnosis of the disease. 
Carotid intima-media thickness (cIMT) measured by
carotid ultrasound was described by Pignoli et al in 1984
and validated by the same authors in 1986. They
conclusively established a strong correlation between the
thickness of the arterial wall, measured by ultrasound,
with the histological findings in these patients.8 Since then,
carotid ultrasound has been known as a technique with
potential applications in the field of atherosclerosis, but 20
years later, it is not part of the routine clinical practice to
diagnose vascular disease, mainly due to the high
variability in the resulting parameters, highly dependent
on the acquisition technique employed. The
recommendations of the XIII European Stroke Conference
in 2004 (Manheim IMT Consensus)9 pconstitute a definite
step forward in generalising the proper technique for
clinical practice. 
Carotid artery ultrasound, which measures cIMT and detects
atheromatous plaques (Figure 1 A and B), is a strong indicator
of overall vascular health. cIMT is a well recognized and
accepted marker to predict cardiovascular disease.10 
In clinical trials, the cIMT is used alongside traditional risk
factors. These trials highlight the usefulness and importance
of using non-invasive techniques to evaluate the effect of
risk factors on the vascular wall. Through the years, clinical
trials have provided evidence corroborating the importance
of measuring cIMT to prevent cardiovascular events (the
thicker the cIMT, the higher the risk of myocardial infarction
and cerebral infarction).11 
cIMT was accepted as a surrogate marker of atherosclerosis
by the US Food and Drug Administration (FDA) and the
European Agency for the Evaluation of Medicinal Products.
At present, cIMT is the noninvasive technique most
frequently used in clinical trials to determine atherosclerosis.
Clinical guidelines and medical societies recommend it to
obtain a more precise evaluation of cardiovascular health in
selected populations,12 and in cardiovascular disease
prevention programmes.13 Upon adjustment for age and sex,
an increase of 0.1 mm in cIMT, indicates a 10%-15%
increase in the risk of myocardial infarction, and a 13%-18%
increase in the risk of stroke.11 
Davidsson14 and coworkers have recently shown, in a
multivariate analysis of 391 men in Sweden, odd ratios for
cardiovascular events of 2.09 (95% confidence interval (CI)
1.05-4.16; p= 0.03) in subjects with atheromatous plaques in
the carotid artery. Nambi et al15 published the latest results
from the ARIC study, demonstrating a correlation between
an increase in cIMT , or the presence of atheromatous
plaques, and the incidence of cardiovascular events. They
reported the predictive role of carotid ultrasound (cIMT and
plaques) in a large epidemiological study of 13,145 healthy
individuals, who presented 1,812 adverse cardiovascular
events over a 15-year follow up. The area under the curve
estimating the sensitivity and accuracy of their logistic
regression analysis increased significantly when cIMT and
the presence of atheromatous plaque were added to the list of
conventional cardiovascular risk factors. 
CAROTID ULTRASOUND IN CHRONIC KIDNEY
DISEASE 
Current tables to estimate cardiovascular risk have not been
designed for CKD patients, whose main cardiovascular risk
factors are different from those in the general population.
CKD patients experience the so-called “reverse
epidemiology”. In studies in haemodialysis patients, no
association was found between serum cholesterol levels or
systolic blood pressure with coronary artery disease,
cerebrovascular disease or peripheral vascular disease.16,17
Furthermore, there are other “non-traditional” and
“emerging” factors that play a role in the pathogenesis of
atherosclerosis in CKD, such as anaemia, chronic
inflammation, oxidative stress, and abnormalities in mineral
metabolism that are not taken into account when using
traditional predictors of cardiovascular risk. 
This evidence, along with the high incidence rate of CVD
among CKD patients,18 supports the use of new, more
sensitive tools for the early detection and prevention of
cardiovascular disease.19 Guidelines from the European
Society of Cardiology recommend a close monitoring of
traditional cardiovascular risk factors in patients with
chronic kidney disease.20 , Furthermore, the National Kidney
Foundation (NKF) recommends the use of carotid ultrasound
for a more precise assessment of cardiovascular health in
kidney disease.21 
Because cardiovascular disease is the main cause of
morbidity and mortality in CKD,22 early diagnosis of vascular
disease using ultrasound techniques is becoming
increasingly widespread in this patient population. 
We lack conclusive evidence on how changes in cIMT relate
to cardiovascular risk factors in CKD, but it has been
reported that cIMT increases as glomerular filtration rate
decreases.23 
Our group has confirmed the high prevalence and severity
of atherosclerosis in patients with different stages of
kidney disease (n=409).24 The diagnostic methods used
were carotid ultrasound and the ankle-brachial index
(ABI). Both tests have been validated as predictors of
adverse cardiovascular events.25 We have developed a
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classification of vascular disease based on the results of
ABI and carotid ultrasound, using for the cIMT reference
intervals adjusted for age and sex. We found that a high
percentage of kidney patients had atheromatous vascular
disease, and this percentage was much higher than in age-
and sex-matched control subjects with a normal kidney
function (n=851). Relevant findings from this study were
the higher prevalence of ATD in patients on dialysis
compared to those at earlier CKD stages, and the lack of
correlation between vascular disease and LDL cholesterol
levels. The presence of atheromatous plaque was higher in
dialysis patients (78.3%)26 compared to pre-dialysis
patients (55.6%)27 or the normal control group (43.2%).
Variables with a positive association with atherosclerosis
included age, dialysis treatment, and serum levels of
plasma C-reactive protein. Being a female was a protective
factor also in CKD.
Carotid ultrasound also offers a critical additional
information, the assessment of vascular calcification.
Vascular calcification is a strong predictor of morbidity and
mortality in the general population and in CKD. In CKD
patients, vascular calcification is more prevalent, appears at
an earlier age, and is more severe.28 The degree of arterial
calcification can be measured using CT to obtain the
Agatston score, which is the only quantitative method
currently available, and therefore it is the gold standard,
mostly used in clinical research. Semi-quantitative methods
have been proven useful, as those described by Adragao and
Kauppila. They employ simple radiology, are more adapted to
clinical practice, and have proved to have a good predictive
power of cardiovascular events in CKD. 
Carotid ultrasound is also the only available technique to
localise the site of calcium deposition within the arterial
wall. Our group has completed an ultrasound study
examining the location of calcium in carotid and femoral
artery wall. The brachial artery served as a negative control
since this area is free of atherosclerosis.29 We observed that
calcification was localized exclusively in the intimal layer,
following two distinct patterns: 1) Calcification of the
atheromatous plaque (Figure 2 A) and 2). Linear
calcification of the intimal layer, anatomically unrelated to
the atheromatous plaque (Figure 2 B). Multivariate analysis
associated this previously unrecognized intimal calcium
location with age, serum levels of phosphate and C-reactive
protein, and with the presence of atheromatosis. These
results underscore the contribution of inflammation and
atheromatosis to the calcification of elastic arteries.
Although serum phosphate levels remain a not fully resolved
issue, we must start focussing on preventing atheromatosis
and decreasing the pro-inflammatory status of CKD patients
as much as possible. 
CONCLUSIONS 
Carotid ultrasound is a tool with a number of advantages
compared to other methods. First, it is easy to use and does
not require complex equipment. It can be performed in
Figure 1. Ultrasound image of carotid arteries 
(A) View of the artery wall for measuring carotid intima-media thickness (cIMT) or the distance between the tunica adventitia
and the intima layer of the arterial wall, at the level of the common carotid artery. Arrows delimit the cIMT; (B) Plaque along
the upper wall of the common carotid artery (plaque defined as cIMT >1.5mm).
A B
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outpatient clinics or at the bedside; and is inexpensive and
non invasive. Secondly, it provides doctors with valuable
information for treatment, including the atheromatous
burden, the severity of the calcification, and the location of
calcium deposition within the vascular wall. Thirdly, it
detects ATD at early stages, prior to the appearance of
atheromatous plaque. Therefore, it constitutes an ideal
technique to obtain evidence-based recommendations for
ATD prevention. 
At present, we lack studies addressing the prognostic value
of either the calcification of atheromatous plaques (type V
plaque according to the American Heart Association) or the
new linear profile of intima calcification in kidney disease
patients. 
The Spanish study NEFRONA (www. nefrona.es) has been
designed to answer important questions on the pathogenesis
and progression of ATD at all CKD stages compared to age-
and sex- matched controls with normal renal function
through measurements of the distinct atherosclerosis and
calcification patterns between groups using arterial
ultrasound. 
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